Teladoc Health (TDOC) to Release Earnings on Thursday

Teladoc Health (NYSE:TDOC) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, April 25th. Analysts expect Teladoc Health to post earnings of ($0.47) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Tuesday, February 20th. The health services provider reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.05. The business had revenue of $660.50 million for the quarter, compared to the consensus estimate of $670.79 million. Teladoc Health had a negative net margin of 8.47% and a negative return on equity of 9.22%. Teladoc Health’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.23) earnings per share. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Trading Up 3.3 %

Shares of Teladoc Health stock opened at $13.75 on Wednesday. The company’s fifty day simple moving average is $15.31 and its 200-day simple moving average is $17.83. The company has a market cap of $2.33 billion, a price-to-earnings ratio of -10.26 and a beta of 0.94. The company has a current ratio of 3.54, a quick ratio of 3.47 and a debt-to-equity ratio of 0.66. Teladoc Health has a 1 year low of $12.85 and a 1 year high of $30.41.

Insider Transactions at Teladoc Health

In other news, CTO Nikolaos P. Nanis sold 2,866 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $41,614.32. Following the sale, the chief technology officer now directly owns 69,850 shares of the company’s stock, valued at approximately $1,014,222. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CTO Nikolaos P. Nanis sold 2,866 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $41,614.32. Following the sale, the chief technology officer now directly owns 69,850 shares of the company’s stock, valued at approximately $1,014,222. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CMO Stephany Verstraete sold 7,945 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $115,361.40. Following the sale, the chief marketing officer now directly owns 56,486 shares in the company, valued at $820,176.72. The disclosure for this sale can be found here. Insiders have sold a total of 135,441 shares of company stock worth $2,038,251 in the last 90 days. Corporate insiders own 1.63% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a research note on Friday, April 5th. Leerink Partnrs restated a “market perform” rating on shares of Teladoc Health in a research note on Monday, February 26th. Barclays lowered their price objective on shares of Teladoc Health from $26.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 21st. Piper Sandler reduced their target price on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, February 21st. Finally, Royal Bank of Canada reduced their target price on Teladoc Health from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, February 21st. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Teladoc Health has a consensus rating of “Hold” and a consensus price target of $22.23.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.